Hulk Hogan, wrestling icon, dies at 71 in Florida home
Investing.com -- Ambu (CSE:AMBUb) posted double-digit organic revenue growth and higher profitability in the second quarter of its 2024/25 fiscal year, but shares dropped more than 11% on Wednesday as results showed a decline in free cash flow.
Organic revenue rose 11.7% to DKK 1,554 million, while reported revenue increased 13.7%.
Organic growth for the first half of the fiscal year reached 15.4%, with reported growth at 16.9%.
Operating profit before special items rose to DKK 224 million, with a margin of 14.4%. For the first half, the margin improved to 15.2%.
Free cash flow before acquisitions declined to DKK 80 million from DKK 128 million, weighed down by higher inventory levels and tax payments.
Endoscopy Solutions grew 13.1% organically in the quarter and 16.7% in the half-year. Within that unit, Pulmonology grew 8.5%, affected by order timing.
The Urology, ENT and GI segment posted 18.3% growth, below previous quarters, though Ambu said it expects growth to accelerate.
Anaesthesia and Patient Monitoring rose 9.8% in the quarter and 13.6% for the half-year, helped by pricing and volume gains.
The company maintained full-year guidance for 11% to 14% organic revenue growth and an EBIT margin before special items between 13% and 15%.
New product launches included the SureSight Connect video laryngoscope, now available in initial markets. Ambu also expanded the use of its aScope 5 Cysto HD in urology procedures.